QYR Market Research Global Onychomycosis (Tinea Unguium) Drug Market | Page 3

QYResearch
• The Onychomycosis (Tinea Unguium) Drug industry was 2,675 million USD in
2017 and is projected to reach 2,905 million USD by 2022, at a CAGR
(Compounded Annual Growth Rate) of 1.66% between 2017 and 2022. The
market is driven by various end-user industries, such as Age under 18, Age
18-50 and Age above 50.
PPT模板下载：www.1ppt.com/moban/
节日PPT模板：www.1ppt.com/jieri/
PPT背景图片：www.1ppt.com/beijing/
优秀PPT下载：www.1ppt.com/xiazai/
Word教程： www.1ppt.com/word/
资料下载：www.1ppt.com/ziliao/
范文下载：www.1ppt.com/fanwen/
教案下载：www.1ppt.com/jiaoan/
字体下载：www.1ppt.com/ziti/
行业PPT模板：www.1ppt.com/hangye/
PPT素材下载：www.1ppt.com/sucai/
PPT图表下载：www.1ppt.com/tubiao/
PPT教程： www.1ppt.com/powerpoint/
Excel教程：www.1ppt.com/excel/
PPT课件下载：www.1ppt.com/kejian/
试卷下载：www.1ppt.com/shiti/
• The industry is concentration, the key brand include Johnson & Johnson,
GSK, Novartis, Pfizer, Valeant Pharma, Kaken Pharmaceutical, Galderma,
Xiuzheng Pharmaceutical, Letai, Qilu Pharmaceutical and so on. Among them,
Johnson & Johnson and GSK are the leaders.
Click to view the full report TOC, figure and tables：
https://www.qyresearch.com/index/detail/445154/global-
onychomycosis-tinea-unguium-drug-market